Biological E partners with China’s Recbio to produce REC603 a 9-valent HPV vaccine in India The collaboration aims to expand ...

The implementation of these three key pillars — vaccination, screening, and treatment — are critical in eliminating cervical ...

Low screening coverage, late diagnoses, high HIV prevalence, and limited access to treatment and vaccines are driving cervical cancer cases and deaths in South Africa. The country has a cervical ...

The US Secretary of Health and Human Services insists he will soon announce the "cause" of autism, but setting a fixed ...

A woman who survived cervical cancer says she is concerned about changes to cervical screening that come into effect today.

According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in UNICEF & PAHO tenders in other markets.

According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in ...

Biological E Ltd. has partnered with Jiangsu Recbio Technology to commercialize the latter's HPV9 vaccine, REC603, in India.

BE to produce and commercialise Recbio's nine-valent HPV vaccine in India and global markets, including participation in ...

HYDERABAD: Jiangsu Recbio Technology Co. Ltd, a leading Chinese biopharmaceutical firm, has entered into a licensing and ...

Jiangsu Recbio Technology Company Limited, a leading Chinese biopharmaceutical company, today announced they have entered into a licensing cooperation agreement, and commenced the technology transfer ...

Biological E. to produce Recbio's HPV9 vaccine in India, expanding global access to cervical cancer prevention.